Information Provided By: 
Fly News Breaks for July 17, 2018
RARE
Jul 17, 2018 | 09:31 EDT
Leerink analyst Joseph Schwartz raised his price target for Ultragenyx to $95 from $68 as a survey of 57 MEDACorp specialists who treat patients with X-linked hypophosphatemia showed a positive view of Crysvita, as they expect to use it extensively among their pediatric patients who should benefit more than adults with XLH. The analyst believes that investor appreciation for Crysvita may continue to grow this year while Ultragenyx advances its gene therapy programs. He reiterates an Outperform rating on the shares.
News For RARE From the Last 2 Days
